Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and even a stall in research and development.

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

The average cost for a Big Pharma ... more intricate and complex research areas, macroeconomic factors, tech advancements and high attrition rates; the pharma cohort spent $7.7 billion on trials ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Biocon's Siddharth Mittal challenges the feasibility of relocating pharma manufacturing to the US from China and India.

Experts say any added costs would be passed onto the ... a major impact on consumers but could impact the research and development areas of pharmaceutical companies. He explained that ...

Clinical trial costs have been rising year-on-year, with companies working to balance the scales and keep studies running despite declining investment. The pharma and biotech sector appeared to be ...

Bachem, a Swiss pharmaceutical ... as they don’t cost as much to develop. This is because brand-name medications are new drugs that require research, development, and clinical trials.